Notable Tuesday Option Activity: GM, LQDA, MP

Liquidia (LQDA) saw 10,829 options contracts trade today—about 1.1 million underlying shares, roughly 55.9% of its one‑month average daily volume—with particularly high activity in the $40 call expiring Jan 23, 2026 (1,601 contracts, ~160,100 shares). MP Materials (MP) registered 43,698 contracts (~4.4 million underlying shares, ~55.5% of its one‑month ADV), led by heavy flow in the $65 put expiring Jan 23, 2026 (2,986 contracts, ~298,600 shares). The outsized options flow relative to average volume indicates notable positioning in both names but the report is descriptive rather than signaling fundamental changes.

Analysis

Market structure: The concentrated flow — ~1.6k Jan‑2026 $40 calls in LQDA (≈160k shares) and ~3.0k Jan‑2026 $65 puts in MP (≈299k shares) — implies large directional exposure sized at ~55% of each stock’s 1‑month ADV, creating immediate delta‑hedging pressure. Winners are option buyers and short gamma market‑makers who can monetize re‑hedging; losers are passive holders if dealer hedging amplifies moves against them over days–weeks.

Competitive dynamics & supply/demand: For MP (materials), heavy put demand signals anticipated downside in demand/realized prices for its commodity exposure or idiosyncratic risk (customer loss/China policy); that can compress pricing power and margins over quarters. For LQDA (biotech), large long‑dated calls point to positioning for a binary upside (clinical/regulatory) through 2025–26 rather than secular market share shifts.

Risk assessment: Tail risks include an adverse FDA/clinical outcome for LQDA or a China export/commodity demand shock for MP — each could move >30–50% and render option premia worthless. Immediate timeframe (days–weeks): gamma squeezes and IV spikes; short term (1–6 months): repricing around earnings/regulatory/data; long term (to Jan 2026): realized fundamentals will dominate. Hidden dependencies include block trade origin (institutional hedge vs directional), dealer net vega exposure, and collateral/financing constraints that can exacerbate moves.

Trade implications & contrarian view: Flows may be overstating directional conviction — large open interest can create self‑reinforcing moves; but if 30‑day IV > historical 90th percentile, buying becomes expensive. Expect squeezes into expiries and potential reversal if underlying fundamentals disagree with options‑driven momentum; monitor open interest concentration (>100k shares at a strike) as a signal for persistent dealer hedging risk.

Key Decisions for Investors

• Establish a tactical 2% long exposure to LQDA via a Jan‑23‑2026 $40/$60 call vertical (debit spread) to cap downside; target gross return >50% if LQDA >$60 by 01/23/2026, stop‑loss: close if spread value falls 40% within 60 days or if 30‑day IV rises above the 90th historical percentile.
• Initiate a 1–2% bearish position on MP: buy Jan‑23‑2026 $65 puts or purchase a $65/$40 put spread (debit) sized to risk no more than 2% portfolio; scale to 3% if MP trades below the $65 strike within 30 trading days or if realized 30‑day vol > implied vol by 20% (momentum confirmation).
• Pair trade for sector neutral exposure: go long LQDA call vertical (1.5%) and short MP equity (1.5%) to isolate options‑flow driven dispersion; rebalance monthly and unwind pair if cumulative P/L hits ±30% or if either company announces a definitive catalyst (FDA decision, quarterly results) within 45 days.